Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 16:28:e938112.
doi: 10.12659/MSM.938112.

A Review of the Roles of Apelin and ELABELA Peptide Ligands in Cardiovascular Disease, Including Heart Failure and Hypertension

Jan Rozwadowski  1 , Sonia Borodzicz-Jażdżyk  1 , Katarzyna Czarzasta  1 , Agnieszka Cudnoch-Jędrzejewska  1
Affiliations
Review

A Review of the Roles of Apelin and ELABELA Peptide Ligands in Cardiovascular Disease, Including Heart Failure and Hypertension

Jan Rozwadowski et al. Med Sci Monit. .

Abstract

Apelin and ELABELA (ELA), which are peptides belonging to the adipokines group, are endogenous peptide ligands of their receptor, APJ, which together constitute the apelinergic system. The apelinergic system is expressed in numerous human tissues and organs, including the heart, blood vessels, adipose tissue, central nervous system, lungs, kidneys, and liver. Apelin, being the most widely studied member of the apelinergic system, plays a key role in the cardiovascular system and exerts a pleiotropic effect in tissues. Under physiological conditions, the peripheral actions of apelin include augmented cardiac contractility, increased left ventricular stroke volume, vasodilation, increased diuresis, and lowered systemic blood pressure. Multiple studies suggest that activation of the apelinergic system exerts beneficial effects on the treatment of cardiovascular diseases (CVD), including hypertension and heart failure, whereas the silencing of the apelin/APJ axis results in attenuation of inflammatory processes and prevents formation of atherosclerotic plaques. As numerous effects of apelin are not entirely explained, further studies of the cardiovascular actions of apelin and ELA are necessary to help establish effective pharmacological treatments of CVDs. This article aims to review the roles of apelin and elabela peptide ligands in cardiovascular diseases, including heart failure and hypertension.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

References

    1. Shin K, Kenward C, Rainey JK. Apelinergic system structure and function. In: Terjung R, editor. Comprehensive physiology [Internet] 1st ed. Wiley; 2017. pp. 407–50. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cphy.c170028[cited 2022 Jan 12] - DOI - PMC - PubMed
    1. Murza A, Sainsily X, Coquerel D, et al. Discovery and structure – activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions. J Med Chem. 2016;59(7):2962–72. - PubMed
    1. Chaves-Almagro C, Castan-Laurell I, Dray C, et al. Apelin receptors: From signaling to antidiabetic strategy. Eur J Pharmacol. 2015;763:149–59. - PubMed
    1. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251(2):471–76. - PubMed
    1. Habata Y, Fujii R, Hosoya M, et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta. 1999;1452(1):25–35. - PubMed